Ozempic and Mental Health: New Study Links Diabetes Drug to Improved Mood and Reduced Substance Leverage

A groundbreaking new study published in The Lancet Psychiatry reveals a significant link between the diabetes drug Ozempic (semaglutide) and improved mental health outcomes. Researchers found that individuals with depression or anxiety who used semaglutide experienced a substantial reduction in sickness absence and hospital care related to psychiatric issues, including a notable decrease in substance use.

The Connection Between Metabolic and Mental Health

Diabetes and obesity are well-established risk factors for mental health conditions, and conversely, mental disorders often increase the risk of developing metabolic diseases. This bidirectional relationship has prompted researchers to investigate whether pharmacological treatments targeting metabolic health could also positively impact mental well-being.

Study Details and Findings

The large, register-based study, a collaboration between the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia, analyzed data from nearly 95,000 participants diagnosed with depression or anxiety. Over 22,480 of these individuals had used GLP-1 receptor agonist drugs like semaglutide. The study followed participants through Swedish national registers from 2009 to 2022, comparing periods of medication use with periods without.

The results demonstrated a compelling association between semaglutide use and improved mental health. Specifically, during periods of semaglutide use, researchers observed:

• A 42% reduction in sickness absence and hospital care due to psychiatric reasons overall.
• A 44% reduction in sickness absence or hospital care related to depression.
• A 38% reduction in sickness absence or hospital care related to anxiety disorders.
• A 47% reduction in sickness absence or hospital care related to substance use.

How Might This Work?

While the exact mechanisms underlying this connection remain under investigation, researchers propose several potential explanations. These include reduced alcohol consumption, improvements in body image related to weight loss, and better glycemic control in individuals with diabetes. There may be direct neurobiological effects, potentially involving changes in the brain’s reward system. Karolinska Institutet researchers note that a previous study found GLP-1 medications associated with a reduced risk of alcohol use disorder, suggesting a potential link to improved mood and anxiety.

Expert Perspective

Research Director Docent Markku Lähteenvuo from the University of Eastern Finland emphasized the strength of the association, stating, “Because this is a registry-based study, we cannot determine exactly why or how these medications affect mood symptoms, but the association was quite strong.” Eurekalert

What Does This Mean for the Future?

These findings suggest that GLP-1 receptor agonists, such as semaglutide and liraglutide, may offer a dual benefit for individuals with co-occurring diabetes, obesity, and mental health conditions. However, researchers caution that further clinical trials are needed to confirm these results and fully elucidate the underlying mechanisms. The study highlights the complex interplay between physical and mental health and opens new avenues for exploring integrated treatment approaches.

Source: Taipale, H., et al. (2026). Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study. The Lancet Psychiatry. DOI: 10.1016/S2215-0366(26)00014-3.